Orakl Oncology SA raises €3m to advance tumour modelling
Paris-based Orakl Oncology SA has raised €3m to develop its techbio platform for precision oncology.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2129 entries already.
Entries by Thomas Gabrielczyk
Precision therapeutics: optimising early discovery
Precision medicine tailors therapeutics to individual patients’ diseases, and is seen as the future of clinical practice. With significant time and financial investments being made in developing therapeutics, the ultimate success of patient-data driven precision therapies hinges on three main factors: the quality of the tissue samples, the associated molecular data, and the analysis used in their development.
Sanofi licences vaccine against bacterial sepsis
French pharma major Sanofi SA will pay US$175m upfront to Janssen Pharmaceuticals, Inc. for commercialisation of a Phase III vaccine against extraintestinal pathogenic E. coli.
Spain set to unveil the potential of the biologisation of medicine and food production
The Spanish EU Council Presidency is to set the course for the internationally competitive use of biotechnology in drug development, plant breeding and food production.
Spain: An overview over a sector that has proven to be strategic
After two years of unprecedented growth driven by the pandemic, investment attracted by Spanish biotech companies has stabilised, and they face significant challenges, positioning biotechnology as a strategic sector for Spain.
Mogrify Ltd extends Series A financing to $46m
British in-vivo cell programming specialist Mogrify Ltd has added US$10m to its US$36m Series A financing.
Seamless Transition: Elevate Immune Cell Expansion from RUO to GMP
Cell Culture Grade AB Serum that can be customised to your specifications.
BioSpain breaking records
With more than 2,100 attendents, 4,700 partnering meetings so far, BioSpain 2023 is set to break records.
Pierre Fabre Laboratories collaborate with Vernalis
Pierre Fabre Laboratories, a leading French medical and beauty care company and Vernalis (R&D) Ltd, a fully owned subsidiary of HitGen Inc. and a specialist in drug discovery announce a long-term partnership for oncology drug discovery.
AI – tool or trouble?
Depending on who you talk to, artificial intelligence (AI) is either a saviour or an enslaver. The concerns range from loss of jobs through to robots running society. However, in the life sciences, the use of AI and machine learning (ML) have created some excitement over their potential applications.